Cobra Biologics is a leading international contract development and manufacturing organisation (CDMO) providing a comprehensive biologics and pharmaceuticals service offering, with multi-functional and experienced project teams nurturing customers’ products through to clinical and commercial manufacture within three GMP approved facilities in the UK and Sweden.
Cobra is a Contract Development and Manufacturing Organisation (CDMO) supporting the global life sciences industry in the development and manufacture of monoclonal antibodies (mAb), recombinant proteins, DNA, viral vectors, microbiota and cell line derived products and pharmaceuticals for clinical trials and commercial supply.
Over 18 years of track record in producing biologics and pharmaceuticals for use in pre-clinical to Phase III clinical trials and commercial supply has given our people a unique knowledge base as both manufacturer and also as service providers for the global life sciences market.
We offer a broad range of integrated and stand-alone development services, bespoke to individual customer requirements, stretching from cell line development to the supply of investigational medicinal product for clinical trials and commercial market supply.
Every program complies with cGMP standards worldwide and is conceived with an unmatched quality derived from the know-how of Cobra’s highly qualified, flexible and dedicated people.
Cobra has three GMP approved facilities; in Sweden our Microbiota production and Fill Finish facility in Matfors, and our Biosimilar and Antibody production facility in Södertälje, and in the United Kingdom our Centre of Excellence for Gene Therapy located in Keele. Our sites offer a comprehensive service to nurture your project from conception to fill and finish.
Cobra takes pride in manufacturing excellence, delivering what we promise and helping our customers to develop drugs for the benefit of patients.
Please visit our website for further information and to get in touch with our team: www.cobrabio.com